Navigation Links
Arpida Announces Full Year 2007 Financial Results
Date:3/13/2008

REINACH, Switzerland, March 13 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the year ending 31 December 2007.

2007 highlights

Major pipeline progress:

- Second pivotal Phase III trial with intravenous iclaprim in cSSSI achieves its pre-specified primary endpoint, as did the first

- Submission of New Drug Application (NDA) for intravenous iclaprim in cSSSI initiated

- First patients enrolled in a Phase II trial with intravenous iclaprim in HAP/VAP/HCAP, an important potential second indication
- Progress of Phase I programme with oral iclaprim

- Promising results of 'first-in-man' studies with AR-709

- Novel antibiotic AR-2474 achieves preclinical proof of concept

- Raised CHF 51.9 million in a secondary offering in March 2007 - Late-stage antifungal therapy added to pipeline via acquisition of TLT Medical Ltd.
- Extensive presence at scientific conferences

- Cash and financial investments of CHF 68.1 million at 31 December 2007

Post-Year-End Events

- Oral iclaprim moves into Phase II efficacy trial in cSSSI

2008 Outlook - Completion of patient enrolment in Phase II trial with oral iclaprim in cSSSI

- Completion of patient enrolment in Phase II trial with intravenous iclaprim in

HAP/VAP/HCAP

- Completion of patient enrolment in Phase III trial with TLT in onychomycosis

- Regulatory review of NDA for intravenous iclaprim in cSSSI in USA

- Submission of application for marketing authorisation in EU

Dr Khalid Islam, President and CEO, commented: "We're tremendously proud of the progress we've achieved in the year under review. By early 2008, we have one product candidate in an NDA filing process, one product in a Phase III, and two additional Phase II development programs. We are expecting the filing of the NDA for intravenous iclaprim in cSSSI to be completed shortly. Mark
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
3. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
4. Arpida-Supported CME Symposium Available Online
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. Arpida Interim Results for six Months to 30 June 2007
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Flagship Biosciences LLC, a leading provider of ... and medical device industries, has announced a laboratory and ... has consolidated its histology and tissue analysis operations from ... just north of Denver. The new addresses are: ... Suite 100, Westminster, CO 80021 , Tissue Image Analysis ...
(Date:8/27/2014)... 27, 2014 Riviera Beach, Florida ... the creation of the Sancilio Scientific Advisory Board ... SCI’s philosophy of looking to nature for pharmaceutical ... actions are based on sound scientific data, analyses, ... Board provides a vehicle for SCI to receive ...
(Date:8/27/2014)... NJ (PRWEB) August 27, 2014 WriteResult, ... services – has once again shown superiority when it ... sponsor by completing the ePRO portion of their most ... The Japan-based pharma chose WriteResult’s digital writing platform ... trials – the first to complete drew data from ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... virus strains has revealed extensive conservation and sharing of ... sharing of specific Replikin gene structures has permitted the ... did for the H5N1 influenza vaccine and the Taura ... to be effective (1,2). This ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot ... replaces Dr. Gregory Stock who will continue to remain active ... , , ... to Signum an outstanding track record of success in growing value at ...
... to conduct the study at the Norris Comprehensive Cancer Center of ... , , ... - Aeterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ... endocrine therapy, today announced that the National Institutes of Health ("NIH") has ...
... Aug. 4 Forte, LLC, today announced ... probate database and estate recovery application that significantly ... OnDemand provides access to a proprietary database of ... matching algorithms that accurately match deceased accounts to ...
Cached Biology Technology:Signum Biosciences Names Braham Shroot as Chief Executive Officer 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 2Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 3Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108 4Forte Launches Probate Finder OnDemand™ 2Forte Launches Probate Finder OnDemand™ 3
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014 /PRNewswire-iReach/ -- The ... hosting the 36 th Annual International Conference (EMBC,14), ... and Towers in Chicago, Illinois , ... than 2,500 global leaders, students, and industry professionals in ... Logo - http://photos.prnewswire.com/prnh/20140827/140333 ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
(Date:8/27/2014)... the main factors thought to be associated with ... are the age of the patient, mechanism of ... time, repair method, operation technique, and repair materials. ... repair of peripheral nerve injuries, there is no ... prognosis, and the dose-effect relationship of the predictors ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3New study throws into question long-held belief about depression 2
... are urgently needed in resource-limited countries. A ... Microbiology colloquium, "Bringing the Lab to the Patient: ... the challenges inherent in bringing new medical devices ... where they are needed most. Point-of-care diagnostics (POCTs) ...
... helped open a new door of possibility in the high-stakes ... an international team, the scientists including Stanford Woods Institute ... found a way to create future ocean conditions in a ... the device can mimic the composition of the future ocean ...
... world dolomite is quite common. More than 90 percent of ... first described scientifically in the 18th century. But who would ... not fully understood, although geologists are aware of large deposits ... years. The process of recent primary dolomite formation is restricted ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2Stanford researchers help predict the oceans of the future with a mini-lab 2How does dolomite form? 2
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
... to Yersinia pestis This antibody ... . Immunogen: Purified ... vaccine strain EV76. ... F1 capsular antigen. There is no ...
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Biology Products: